FDA Accepts Resubmission of Lorcaserin NDA

Arena Pharmaceuticals and Eisai announced that the FDA has accepted for filing and review Arena’s resubmission of the New Drug Application for lorcaserin. The FDA considers the resubmission a complete Class II response and assigned a new Prescription Drug User Fee Act target date of June 27.
The Sacramento Bee